Clinical Trial Update: Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) [Phase 3]

View source ↗

Summary

A Phase 3 trial (MK-3475-966/KEYNOTE-966) evaluating pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin as first-line therapy fo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• KEYTRUDA (PEMBROLIZUMAB)
• Platinol (cisplatin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Biliary Tract Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2023-12-22